342 related articles for article (PubMed ID: 25305585)
1. In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications.
Mori M; Almeida PV; Cola M; Anselmi G; Mäkilä E; Correia A; Salonen J; Hirvonen J; Caramella C; Santos HA
Eur J Pharm Biopharm; 2014 Nov; 88(3):635-42. PubMed ID: 25305585
[TBL] [Abstract][Full Text] [Related]
2. Platelet Lysate-Modified Porous Silicon Microparticles for Enhanced Cell Proliferation in Wound Healing Applications.
Fontana F; Mori M; Riva F; Mäkilä E; Liu D; Salonen J; Nicoletti G; Hirvonen J; Caramella C; Santos HA
ACS Appl Mater Interfaces; 2016 Jan; 8(1):988-96. PubMed ID: 26652045
[TBL] [Abstract][Full Text] [Related]
3. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers.
Shrestha N; Shahbazi MA; Araújo F; Zhang H; Mäkilä EM; Kauppila J; Sarmento B; Salonen JJ; Hirvonen JT; Santos HA
Biomaterials; 2014 Aug; 35(25):7172-9. PubMed ID: 24844163
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size.
Santos HA; Riikonen J; Salonen J; Mäkilä E; Heikkilä T; Laaksonen T; Peltonen L; Lehto VP; Hirvonen J
Acta Biomater; 2010 Jul; 6(7):2721-31. PubMed ID: 20036766
[TBL] [Abstract][Full Text] [Related]
5. Cellular interactions of surface modified nanoporous silicon particles.
Bimbo LM; Sarparanta M; Mäkilä E; Laaksonen T; Laaksonen P; Salonen J; Linder MB; Hirvonen J; Airaksinen AJ; Santos HA
Nanoscale; 2012 May; 4(10):3184-92. PubMed ID: 22508528
[TBL] [Abstract][Full Text] [Related]
6. Topical hydrogel matrix loaded with Simvastatin microparticles for enhanced wound healing activity.
Yasasvini S; Anusa RS; VedhaHari BN; Prabhu PC; RamyaDevi D
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():160-167. PubMed ID: 28024572
[TBL] [Abstract][Full Text] [Related]
7. New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles.
Vale N; Mäkilä E; Salonen J; Gomes P; Hirvonen J; Santos HA
Eur J Pharm Biopharm; 2012 Jun; 81(2):314-23. PubMed ID: 22418076
[TBL] [Abstract][Full Text] [Related]
8. Controlled drug delivery from composites of nanostructured porous silicon and poly(L-lactide).
McInnes SJ; Irani Y; Williams KA; Voelcker NH
Nanomedicine (Lond); 2012 Jul; 7(7):995-1016. PubMed ID: 22394185
[TBL] [Abstract][Full Text] [Related]
9. Synergistic and On-Demand Release of Ag-AMPs Loaded on Porous Silicon Nanocarriers for Antibacteria and Wound Healing.
Jin Y; Yang Y; Duan W; Qu X; Wu J
ACS Appl Mater Interfaces; 2021 Apr; 13(14):16127-16141. PubMed ID: 33787222
[TBL] [Abstract][Full Text] [Related]
10. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles.
Bimbo LM; Mäkilä E; Raula J; Laaksonen T; Laaksonen P; Strommer K; Kauppinen EI; Salonen J; Linder MB; Hirvonen J; Santos HA
Biomaterials; 2011 Dec; 32(34):9089-99. PubMed ID: 21864895
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery.
Kilpeläinen M; Mönkäre J; Vlasova MA; Riikonen J; Lehto VP; Salonen J; Järvinen K; Herzig KH
Eur J Pharm Biopharm; 2011 Jan; 77(1):20-5. PubMed ID: 20965250
[TBL] [Abstract][Full Text] [Related]
12. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.
Limnell T; Riikonen J; Salonen J; Kaukonen AM; Laitinen L; Hirvonen J; Lehto VP
Int J Pharm; 2007 Oct; 343(1-2):141-7. PubMed ID: 17600644
[TBL] [Abstract][Full Text] [Related]
13. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.
Huotari A; Xu W; Mönkäre J; Kovalainen M; Herzig KH; Lehto VP; Järvinen K
Int J Pharm; 2013 Sep; 454(1):67-73. PubMed ID: 23834832
[TBL] [Abstract][Full Text] [Related]
14. In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart.
Tölli MA; Ferreira MP; Kinnunen SM; Rysä J; Mäkilä EM; Szabó Z; Serpi RE; Ohukainen PJ; Välimäki MJ; Correia AM; Salonen JJ; Hirvonen JT; Ruskoaho HJ; Santos HA
Biomaterials; 2014 Sep; 35(29):8394-405. PubMed ID: 24985734
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi microparticle surface chemistry on peptide YY3-36 release.
Kovalainen M; Mönkäre J; Mäkilä E; Salonen J; Lehto VP; Herzig KH; Järvinen K
Pharm Res; 2012 Mar; 29(3):837-46. PubMed ID: 22033881
[TBL] [Abstract][Full Text] [Related]
16. "Thunderstruck": Plasma-Polymer-Coated Porous Silicon Microparticles As a Controlled Drug Delivery System.
McInnes SJ; Michl TD; Delalat B; Al-Bataineh SA; Coad BR; Vasilev K; Griesser HJ; Voelcker NH
ACS Appl Mater Interfaces; 2016 Feb; 8(7):4467-76. PubMed ID: 26836366
[TBL] [Abstract][Full Text] [Related]
17. Development of chitosan oleate ionic micelles loaded with silver sulfadiazine to be associated with platelet lysate for application in wound healing.
Dellera E; Bonferoni MC; Sandri G; Rossi S; Ferrari F; Del Fante C; Perotti C; Grisoli P; Caramella C
Eur J Pharm Biopharm; 2014 Nov; 88(3):643-50. PubMed ID: 25128852
[TBL] [Abstract][Full Text] [Related]
18. Porous silicon-cyclodextrin based polymer composites for drug delivery applications.
Hernandez-Montelongo J; Naveas N; Degoutin S; Tabary N; Chai F; Spampinato V; Ceccone G; Rossi F; Torres-Costa V; Manso-Silvan M; Martel B
Carbohydr Polym; 2014 Sep; 110():238-52. PubMed ID: 24906752
[TBL] [Abstract][Full Text] [Related]
19. Microfluidic templated mesoporous silicon-solid lipid microcomposites for sustained drug delivery.
Liu D; Herranz-Blanco B; Mäkilä E; Arriaga LR; Mirza S; Weitz DA; Sandler N; Salonen J; Hirvonen J; Santos HA
ACS Appl Mater Interfaces; 2013 Nov; 5(22):12127-34. PubMed ID: 24175755
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity assessment of porous silicon microparticles for ocular drug delivery.
Korhonen E; Rönkkö S; Hillebrand S; Riikonen J; Xu W; Järvinen K; Lehto VP; Kauppinen A
Eur J Pharm Biopharm; 2016 Mar; 100():1-8. PubMed ID: 26686646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
